Background: The diffuse neuroimmunoendocrine system (DNIES) is a universal system of response, control and organism protection. Platelets are cells of DNIES producing and storing melatonin which plays an important role in the regulation of physiological processes in the human body, under normal conditions and in pathology. Our previous study has revealed a low basic melatonin production in patients with aspirin-induced asthma (AIA). It has been suggested that low daytime production of melatonin in patients with AIA is attributable to the reduction in its synthesis in platelets in this group of patients. The objective of this study was to investigate this hypothesis.
Materials And Methods: The melatonin expression in platelets has been studied by means of indirect immunofluorescence in nine patients with AIA and 14 healthy subjects.
Results: The results of the study have revealed that only 13·1 ± 1·3% of platelets in patients with AIA have shown melatonin-specific luminescence, compared to 97·7 ± 0·6% of platelets in healthy subjects (P < 0·001). No melatonin expression has been observed in the rest of platelets in patients with AIA. No significant difference between the degree of the melatonin luminescence in platelets of the patients with AIA and control group has been found.
Conclusions: It can be concluded that the reduced melatonin synthesis in platelets of patients with AIA may determine a low daytime melatonin production and may lead to impairments in platelet receptors and ion channels. This results in disturbances in calcium homoeostasis, which may be a cause of platelet activation and pathological response to exogenous melatonin and acetylsalicylic acid.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2362.2011.02484.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Approaches and Challenges in Managing Treatment-Resistant Hypertension: A Case Report.
Cureus
December 2024
Internal Medicine, University of Chicago Medicine AdventHealth La Grange, Chicago, USA.
Treatment-resistant hypertension (TRH) is defined by consistently elevated blood pressure readings unresponsive to medical management. In clinical practice, it poses a significant challenge due to the intertwining variables that may cause the issue to persist such as lifestyle, genetics, and other comorbidities, as opposed to simple medication non-adherence. This report describes the case of a 68-year-old female patient presenting for a routine follow-up with persistently elevated ambulatory blood pressure readings.
View Article and Find Full Text PDFActivity impairment, work productivity, health-related quality-of-life, and costs associated with uncomplicated urinary tract infection among females in Germany.
PLoS One
January 2025
Department of Epidemiology, GSK, Collegeville, Pennsylvania, United States of America.
Uncomplicated urinary tract infections (uUTIs) represent a sizable healthcare burden with a substantial negative impact on patients' health-related quality-of-life (HRQoL). However, the HRQoL impact of uUTI from the patient perspective is under-represented in research. A cross-sectional online survey assessed activity impairment and work productivity, HRQoL, costs, and treatment satisfaction of female patients with uUTIs in the US; the current study applies this earlier methodology to Germany to provide a European perspective.
View Article and Find Full Text PDF12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
EClinicalMedicine
August 2024
Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom.
Background: While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of semaglutide on brain health. This study provides robust estimates of the risk of neurological and psychiatric outcomes following semaglutide use compared to three other antidiabetic medications.
View Article and Find Full Text PDFMelatonin, an Antitumor Necrosis Factor Therapy.
J Pineal Res
January 2025
Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Tumor necrosis factor (TNF) is a biomarker of inflammation whose levels are elevated in patients with several diseases associated with dysregulation of the immune response. The main limitations of currently used anti-TNF therapies are the induction of immunodepression, which in many cases leads to serious adverse effects such as infection and cancer, and the inability to cross the blood-brain barrier in neuroinflammatory conditions. Melatonin, in addition to being a chronobiotic compound, is widely known for its antioxidant and immunomodulatory capacity to control inflammatory processes in different pathological contexts.
View Article and Find Full Text PDFThymidine phosphorylase participates in platelet activation and promotes inflammation in rheumatoid arthritis.
Toxicol Appl Pharmacol
December 2024
Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Electronic address:
The elevated risk of cardiovascular disease (CVD) associated with inflammatory rheumatic diseases has long been recognized. Patients with established rheumatoid arthritis (RA) have a higher mortality rate compared to the general population due to abnormal platelet activation. Thymidine phosphorylase (TYMP) plays a crucial role in platelet activation and thrombosis, following bridging the link between RA and CVD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!